ConductScience.org, home

Trial · NCT01951339

Results by group32

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Peak Oxygen Consumption (VO2peak).Sitagliptin Plus PlaceboPre-intervention1893Standard Deviation 138ml/min
Peak Oxygen Consumption (VO2peak).Glimepiride Plus PlaceboPre-intervention1953Standard Deviation 113ml/min
Peak Oxygen Consumption (VO2peak).Sitagliptin Plus PlaceboPost-intervention1849Standard Deviation 135ml/min
Peak Oxygen Consumption (VO2peak).Glimepiride Plus PlaceboPost-intervention1881Standard Deviation 151ml/min
Changes From Baseline in 31P Measurement: Phosphocreatine Time ConstantSitagliptin Plus PlaceboPre-intervention34.1Standard Deviation 7.3seconds
Changes From Baseline in 31P Measurement: Phosphocreatine Time ConstantGlimepiride Plus PlaceboPre-intervention30.9Standard Deviation 3.9seconds
Changes From Baseline in 31P Measurement: Phosphocreatine Time ConstantSitagliptin Plus PlaceboPost-intervention26.6Standard Deviation 2.9seconds
Changes From Baseline in 31P Measurement: Phosphocreatine Time ConstantGlimepiride Plus PlaceboPost-intervention29.6Standard Deviation 3.6seconds
Change in Oxygen Uptake Kinetics (VO2 Kinetics)Sitagliptin Plus PlaceboPre-intervention56.2Standard Deviation 5.0seconds
Change in Oxygen Uptake Kinetics (VO2 Kinetics)Glimepiride Plus PlaceboPre-intervention54.2Standard Deviation 7.3seconds
Change in Oxygen Uptake Kinetics (VO2 Kinetics)Sitagliptin Plus PlaceboPost-intervention67.5Standard Deviation 8.0seconds
Change in Oxygen Uptake Kinetics (VO2 Kinetics)Glimepiride Plus PlaceboPost-intervention54.6Standard Deviation 4.3seconds
Changes From Baseline in 31P Measurement: Free Pi Time ConstantSitagliptin Plus PlaceboPre-intervention29.73Standard Deviation 10.16seconds
Changes From Baseline in 31P Measurement: Free Pi Time ConstantGlimepiride Plus PlaceboPre-intervention28.54Standard Deviation 10.44seconds
Changes From Baseline in 31P Measurement: Free Pi Time ConstantSitagliptin Plus PlaceboPost-intervention27.94Standard Deviation 3.82seconds
Changes From Baseline in 31P Measurement: Free Pi Time ConstantGlimepiride Plus PlaceboPost-intervention26.15Standard Deviation 5.60seconds
Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) PeaksSitagliptin Plus PlaceboPre-intervention8.19Standard Deviation 0.22mM
Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) PeaksGlimepiride Plus PlaceboPre-intervention7.93Standard Deviation 0.58mM
Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) PeaksSitagliptin Plus PlaceboPost-intervention12.66Standard Deviation 13.59mM
Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) PeaksGlimepiride Plus PlaceboPost-intervention8.02Standard Deviation 0.29mM

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01951339/results